Center for Medical Weight Loss; Long Island Weight Loss Institute

Center for Medical Weight Loss, operating as Long Island Weight Loss Institute since 2001, provides physician-supervised weight management programs in East Meadow, NY, under the medical direction of Dr. Michael Kaplan, MD. The practice employs board-certified physicians who design individualized treatment protocols addressing obesity, type 2 diabetes, and hypertension through evidence-based medical interventions. With over two decades serving Nassau County communities, the clinic integrates pharmaceutical weight loss agents with metabolic health optimization strategies tailored to each patient's laboratory findings and cardiovascular risk profile.

The institute prescribes GLP-1 receptor agonist medications including semaglutide and tirzepatide for patients meeting clinical criteria for medical weight loss therapy. These peptide-based treatments work by regulating appetite signals and glucose metabolism, and are administered as part of comprehensive programs that include baseline metabolic panels, body composition analysis, and ongoing monitoring of blood pressure and glycemic control. Dr. Kaplan and his medical team adjust medication dosing based on patient response and tolerance, with protocols designed for individuals who have not achieved adequate results through lifestyle modification alone. The practice accepts various insurance plans and conducts thorough eligibility verification to determine coverage for weight loss medications and medical visits.

Dr. Michael Kaplan brings his board certification and extensive experience in obesity medicine to patient consultations conducted at the East Meadow office. The medical staff performs comprehensive intake assessments that include reviewing previous weight loss attempts, current medications, comorbid conditions such as diabetes and hypertension, and establishing realistic weight reduction targets. Patients receive detailed explanations of how semaglutide and tirzepatide function at the receptor level, expected timelines for weight reduction, and potential side effects requiring medical attention. The practice emphasizes patient education, ensuring individuals understand the mechanism of action behind their prescribed therapies and the importance of adherence to follow-up schedules for dose titration and safety monitoring.

Patients attending Long Island Weight Loss Institute can expect in-person consultations where vital signs are measured, progress is documented, and treatment plans are modified based on objective health markers. The front desk staff manages appointment scheduling and insurance coordination, while the clinical team addresses patient questions regarding medication administration, dietary adjustments, and management of treatment-related effects. Follow-up visits typically occur at intervals determined by the prescribing physician, with more frequent monitoring during initial dose escalation phases. The practice also offers telehealth consultations for established patients within New York State, providing continuity of care for medication management and progress assessments when in-person visits are not feasible.

What distinguishes this East Meadow practice is its integration of weight loss pharmacotherapy with management of obesity-related comorbidities under one medical team. Patients receiving semaglutide or tirzepatide for weight reduction simultaneously benefit from hypertension monitoring and diabetes management, with adjustments made to antihypertensive and glucose-lowering medications as weight loss progresses and metabolic parameters improve. The clinic's longevity since 2001 reflects sustained expertise in navigating the evolving landscape of obesity pharmacotherapy, from earlier-generation medications to current incretin-based therapies. Dr. Kaplan's approach centers on treating obesity as a chronic medical condition requiring ongoing clinical oversight rather than a short-term dietary challenge, with treatment plans designed for long-term metabolic health improvement rather than rapid unsustainable weight reduction.